Evidence map›Paper›PMID 31620531›Full record

ArticleACG case reports journal2019

Now You See It, Now You Do Not: A Case of Infliximab-Induced Vanishing Bile Duct Syndrome.

Parth Shah, Brent Larson, Marc Wishingrad, Nicholas Nissen, Einar Björnsson, Vinay Sundaram

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in ACG case reports journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Parth ShahDepartment of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Brent LarsonDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Marc WishingradDepartment of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA.
Nicholas NissenDepartment of General Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Einar BjörnssonDepartment of Internal Medicine, The National University Hospital of Iceland, Reykjavik, Iceland.
Vinay SundaramDepartment of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA.
Cedars-Sinai Medical Center · USNational University Hospital of Iceland · IS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infliximab is a commonly used antitumor necrosis factor alpha agent, especially in patients with inflammatory bowel disease. It has been associated with drug-induced liver injury including immunologic reactions, with rare cases of acute liver failure. We describe a patient with chronic cholestasis and loss of intrahepatic bile ducts after therapy with infliximab for refractory ulcerative colitis consistent with a diagnosis of vanishing bile duct syndrome. About 3 months after the initial infusion, the patient developed subfulminant liver failure and required liver transplantation.

Identifiers

PMID31620531
PMCPMC6722359
OpenAlexW2963140857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.